「the first」の検索結果
23件：11～15件目を表示
-
ers: Osaka, Japan; President: Mr. Shuhei Yoshida) today announces that it has received approval for the marketing of “Mytear Lumify” (OTC drug requiring instruction by pharmacist, hereinafter this &qu...
https://www.senju.co.jp/system/files/content_news/2024-08/ENG_20240903_0.pdf -
g approval in Japan as of December 22, 2025. Avarept® Ophthalmic suspension 0.3% represents a novel therapy for DED with Transient Receptor Potential cation channel subfamily V member 1 (TRPV1)*1 anta...
https://www.senju.co.jp/system/files/content_news/2025-12/ENG_20251222_0.pdf -
treatment for Dry Eye Disease (DED), has been launched in Japan today. Avarept® represents a novel therapy for DED with Transient Receptor Potential cation channel subfamily V member 1 (TRPV1) *1 ant...
https://www.senju.co.jp/system/files/content_news/2026-04/ENG_20260406.pdf -
g approval in Japan as of December 22, 2025. Avarept® Ophthalmic suspension 0.3% represents a novel therapy for DED with Transient Receptor Potential cation channel subfamily V member 1 (TRPV1)*1 anta...
https://www.senju.co.jp/system/files/content_news/2025-12/ENG_20251222.pdf -
treatment for Dry Eye Disease (DED), has been launched in Japan today. Avarept® represents a novel therapy for DED with Transient Receptor Potential cation channel subfamily V member 1 (TRPV1) *1 ant...
https://www.senju.co.jp/system/files/content_news/2026-04/ENG_20260406_0.pdf